跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

E-068

Supelco

依维莫司 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C53H83NO14
CAS号:
159351-69-6
分子量:
958.22
MDL號碼:
MFCD00929329
分類程式碼代碼:
41116107
PubChem物質ID:
329798983
NACRES:
NA.24

等級

certified reference material

品質等級

300

形狀

liquid

特點

(Snap-N-Spike®)

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

濃度

1.0 mg/mL in acetonitrile

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

運輸包裝

dry ice

儲存溫度

−70°C

SMILES 字串

N21[C@@H](CCCC2)C(=O)O[C@@H](CC(=O)[C@@H](\C=C(\[C@H]([C@H](C(=O)[C@@H](C[C@@H](\C=C\C=C\C=C(\[C@H](C[C@H]4O[C@]([C@@H](CC4)C)(C(=O)C1=O)O)OC)/C)C)C)OC)O)/C)C)[C@@H](C[C@H]3C[C@H]([C@@H](CC3)OCCO)OC)C

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI 密鑰

HKVAMNSJSFKALM-GKUWKFKPSA-N

基因資訊

human ... FKBP1A(2280)

相关类别

一般說明

以Zortress®、Certican和Afinitor®等商品名出售的依维莫司是一种免疫抑制剂，可用于防止器官移植排斥并治疗肾细胞癌和其他肿瘤。此认证加标溶液®适合用作从校准物、对照品或线性标准品的起始材料，通过LC/MS或GC/MS对患者全血样品中的依维莫司进行治疗性药物监测或临床和诊断检验。

法律資訊

Afinitor is a registered trademark of Novartis AG
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zortress is a registered trademark of Novartis AG

象形圖

FlameExclamation mark
GHS02,GHS07

訊號詞

Danger

危險分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

35.6 °F - closed cup

閃點（°C）

2.0 °C - closed cup

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Elisavet Paplomata et al.
Breast cancer research and treatment, 140(3), 453-462 (2013-08-03)
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR), which has been approved in combination with exemestane for hormone receptor-positive (HR) breast cancer after failure of treatment with non-steroidal aromatase inhibitors. Everolimus is generally very well
Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities.
Piguet AC, Majumder S, Maheshwari U, et al.
Clinical Science, 126(11), 775-784 (2014)
Hirohiko Yasui et al.
Cancer letters, 347(1), 114-122 (2014-02-05)
We examined efficacy of the mTOR inhibitor RAD001 to seek novel therapies for synovial sarcoma (SS). Although RAD001 had significant anti-tumor effects, its sensitivity differed among cell lines. Phospho-receptor tyrosine kinase (RTK) array analyses revealed c-MET phosphorylation in highly mTOR
Matteo Santoni et al.
Biochimica et biophysica acta, 1845(2), 221-231 (2014-02-01)
The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Treatment of metastatic renal cell carcinoma (mRCC) has improved significantly with the advent of agents targeting the mTOR pathway, such as temsirolimus and everolimus. Unfortunately, a
Michael Cardamone et al.
The Journal of pediatrics, 164(5), 1195-1200 (2014-02-13)
To evaluate the efficacy and side effects of oral mammalian target of rapamycin (mTOR) inhibitors in children and adolescents with tuberous sclerosis complex (TSC) and intractable epilepsy or subependymal giant cell astrocytoma (SEGA). Single-center series of 13 children and adolescents
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持